Arrowhead Pharmaceuticals Inc.

ARWR | NASDAQ

Price Alert Chart Builder DCF Calculator

$59.70

-$0.20 (-0.33%)

Nov 2, 2026, 12:30 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.33%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

51.6

+3.5 pts

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Sector Rank #245/1028 (Top 24%)

Full Analysis

Key Statistics

Market Data

Market Cap $8.43B

1D Range

59.52 61.17

52W Range

37.85 89.59

Valuation (TTM)

PE -26.74

PB 18.18

EV/EBITDA -55.04

Valuation (NTM)

Forward PE N/A

Forward PEG -0.71

Price Target $101.56

Cash Flow

FCF Yield -0.9%

SBC Adj. FCF Yield -1.7%

SBC Impact -93.2%

Margins

Gross Margin 100.0%

Operating Margin -33.8%

FCF Margin -11.2%

Growth (CAGR)

Revenue 3Y | 5Y 37.7% | 44.1%

Dil EPS 3Y | 5Y 44.3% | -5.0%

FCF 3Y | 5Y 109.7% | 19.0%

Returns

ROA -15.2%

ROE -60.5%

ROIC -12.1%

Financial Health

Net Cash

$737.89M

Current Ratio 5.90

Interest Coverage -2.45

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challeng...

Sector Healthcare

Industry Biotechnology

Employees 711

IPO Date Dec 16, 1993

Website arrowheadpharma.com

Fiscal Year October - September

Full Company Profile

Latest News

10 hours ago · businesswire.com

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week's American Heart Association Scientific Sessions in Chicago. AHA 2026 Oral Presentations Date & Time: Saturday, November 7, 3:15 – 4:30 pm CT Session Title: FS.05: Featured Science Session on Novel Lipid Lowering Therapies Location: Learning Studio 2‚ Science and Technology Hall‚ South Hall Title: First-in-Human Trial of a Dual Functional RNAi Mo.

19 days ago · seekingalpha.com

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript

$Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher$

1 month ago · seekingalpha.com

Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher

Arrowhead Pharmaceuticals is positioned to challenge Ionis in severe hypertriglyceridemia (sHTG) with plozasiran, leveraging a faster launch via a $215M priority review voucher. ARWR's SHASTA-3 and SHASTA-4 Phase III data show plozasiran achieves 79–81% median triglyceride reductions and favorable safety, with quarterly dosing and no liver fat or thrombocytopenia signals. Current financials reflect partner-driven revenue and a strategic buildout for sHTG; liquidity of ~$1.35B post-voucher supports operations into early 2028, but further funding may be needed as SG&A rises.

1 month ago · marketbeat.com

Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands

Arrowhead Pharmaceuticals NASDAQ: ARWR is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs targeting cardiometabolic disease, obesity and central nervous system disorders.

2 months ago · seekingalpha.com

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

2 months ago · seekingalpha.com

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · businesswire.com

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC.